Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 14, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2019View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 8, 2019View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GJan 31, 2019View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GJan 31, 2019View HTMLDownload DOCDownload PDF

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information